CN111643681A - Nr4a3在促进神经再生和修复神经损伤方面的应用 - Google Patents
Nr4a3在促进神经再生和修复神经损伤方面的应用 Download PDFInfo
- Publication number
- CN111643681A CN111643681A CN202010558904.1A CN202010558904A CN111643681A CN 111643681 A CN111643681 A CN 111643681A CN 202010558904 A CN202010558904 A CN 202010558904A CN 111643681 A CN111643681 A CN 111643681A
- Authority
- CN
- China
- Prior art keywords
- nr4a3
- cells
- drg
- nerve injury
- repairing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
Abstract
本发明公开Nr4a3在制备促进神经再生和修复神经损伤药物中的应用;所述神经损伤为周围神经系统坐骨神经损伤。所述药物以Nr4a3作为分子干预靶点,干扰Nr4a3,促进DRG神经元轴突生长。本发明还公开一种促进神经再生和修复神经损伤药物,所述药物至少包括Nr4a3的小干扰RNA。本发明另外还公开Nr4a3在促进神经再生和修复神经损伤方面的应用,其特征在于,包括以下过程:S1、大鼠DRG神经元体外培养并检测其中Nr4a3的表达情况;S2、体外干扰Nr4a3,能够促进DRG神经元轴突生长。本发明以Nr4a3作为分子干预靶点,干扰Nr4a3,促进DRG神经元轴突生长,为神经损伤后的治疗提供新的靶点。
Description
技术领域
本发明属于生物医学技术领域,涉及Nr4a3在促进神经再生和修复神经损伤方面的应用;具体涉及Nr4a3在制备促进神经再生和修复神经损伤药物中的应用、Nr4a3在制备促进神经再生和修复神经损伤药物中的应用及Nr4a3在促进神经再生和修复神经损伤方面的应用。
背景技术
周围神经受损后可以自发的再生,但由于再生速度有限,功能难以恢复,致残率高,给社会及家庭造成了极大的经济和伦理负担。充分深入的理解周围神经损伤再生的细胞与分子机制,有助于提高周围神经功能修复的成功率,同时这也为解决中枢神经系统再生中遇到的问题提供参考,具有重大的理论基础和潜在的临床价值。本发明探索基因Nr4a3在促进神经再生和修复神经损伤方面的应用。
发明内容
发明目的:针对现有技术中存在问题或不足,本发明提供一种Nr4a3在促进神经再生和修复神经损伤方面的应用。
为实现上述发明目的,本发明的实施例提供Nr4a3在制备促进神经再生和修复神经损伤药物中的应用。
进一步的,所述神经损伤为周围神经系统坐骨神经损伤。
进一步的,所述药物以Nr4a3作为分子干预靶点,干扰Nr4a3,促进DRG神经元轴突生长。
本发明的实施例还一种促进神经再生和修复神经损伤药物,其特征在于,所述药物至少包括Nr4a3的小干扰RNA。
进一步的,所述Nr4a3的小干扰RNA包括Nr4a3 siRNA-1或Nr4a3 siRNA-2,所述Nr4a3 siRNA-1序列为GCGTACAGATAGTCTGAAA,所述Nr4a3siRNA-2序列为GCCTTTGATCAAGATGGAA。
本发明的实施例另外还Nr4a3在促进神经再生和修复神经损伤方面的应用,其特征在于,包括以下过程:S1、大鼠DRG 神经元体外培养并检测其中Nr4a3的表达情况;S2、体外干扰Nr4a3,能够促进DRG神经元轴突生长。
其中,所述步骤S1具体包括以下过程:
S1-1、原代DRG神经元细胞的提取
S1-1-1、DRG 神经元来自成年雄性大鼠,将背根神经节取出后放到解剖液 HA 中,加3.3 mg/ml 胶原酶消化,37 ℃,90 min;
S1-1-2、弃胶原酶,加 0.25%的胰酶消化,37 ℃,20 min;
S1-1-3、用含有10%胎牛血清的 PBS 终止胰酶作用,离心后弃上清;
S1-1-4、用 15%的牛血清白蛋白悬浮细胞后离心,弃掉上清;
S1-1-5、用神经元培养基重悬细胞,过200目筛网后种到用多聚赖氨酸包被的板孔里;
S1-2、DRG细胞RNA提取及qRT-PCR
S1-2-1、收取体外培养不同时间点的DRG神经元细胞,提取RNA;
S1-2-2、使用 TaqMan 反转录试剂盒进行逆转录;
S1-2-3、逆转录后,进行qRT-PCR,以GAPDH作为内参, PCR仪反应程序: Stage 1:95℃2 min, Stage 2:95℃ 15 s,60℃ 1 min;Stage 3:95℃ 15 s,60℃ 1 min,95℃ 15 s;Nr4a3引物序列forward: 5’-CGAGCTCGAAGCCTGAGCAGAGAGCTACTT -3’, reverse: 5’-CCGCTCGAGCGGAGACTAAAGCAAAAATGAT -3’;
S1-3、Western blot
S1-3-1、收取体外培养不同时间点的DRG神经元细胞,PBS 润洗一遍,加入的细胞裂解液,冰上裂解 5-10 min,至细胞完全裂解;
S1-3-2、4 ℃离心,13000 rpm,10 min,收集上清;BCA法蛋白定量;
S1-3-3、进行SDS-PAGE电泳,转膜后用5%的脱脂牛奶,室温封闭2 h;
S1-3-4、孵育一抗,用一抗稀释液稀释 Rabbit anti-Nr4a3 Polyclonal antibody(1:400),室温孵育,过夜;1×TBS 洗3遍,每遍 10 min;
S1-3-5、用 5%的脱脂牛奶稀释二抗羊抗兔 HRP(1:1000),室温孵育,120 min;1×TBST洗 3 遍,每遍 10min,1×TBS 洗 1 遍,10 min;
S1-3-6、在膜上孵育 ECL 显色液,室温,1-3 min;显影,观察结果;待胶片晾干后用扫膜仪将结果传输到电脑。
其中,所述步骤S2具体包括以下过程:
S2-1、DRG神经元细胞siRNA转染
Nr4a3 siRNA-1序列:GCGTACAGATAGTCTGAAA,Nr4a3 siRNA-2序列:GCCTTTGATCAAGATGGAA,使用浓度100 nM;
使用转染试剂 Lipofectamine™ RNAiMAX 在原代培养的DRG神经元细胞中转染Nr4a3siRNA及阴性对照,12 h 后更换为正常神经元培养基,48 h后提取细胞总RNA,进行qRT-PCR,检测siRNA处理后,DRG神经元细胞中Nr4a3的mRNA表达水平;
S2-2、细胞免疫荧光染色及轴突生长长度测量
S2-2-1、DRG神经元细胞Nr4a3 siRNA处理72 h后将细胞培养基弃掉后,用 PBS 润洗一遍,加入4%的多聚甲醛,固定30 min;
S2-2-2、弃掉多聚甲醛后,PBS 洗三遍,每遍5 min;
S2-2-3、加入免疫组化封闭液,室温封闭1 h;
S2-2-4、用免疫组化一抗稀释液稀释一抗anti-Tuj1 antibody(1:200,Sigma),加好一抗后,4 ℃过夜; 弃掉一抗,PBS洗3遍,每遍5 min;
S2-2-5、用免疫组化二抗稀释液稀释荧光二抗Cy3 sheep anti-rabbit IgG (1:400,Sigma),加好二抗后,避光室温2 h;弃掉二抗,PBS洗3遍,每遍5 min;
S2-2-6、用PBS稀释Hoechest,加好Hoechest后,室温10 min; 弃掉Hoechest,PBS洗3遍,每遍5 min;
S2-2-7、加入适量荧光封片液,ZEISS正置荧光显微镜下观察,拍照;观察突起的生长情况,拍照并统计各组最长突起长度和各组突起长度的分布。
本发明的上述技术方案的有益效果如下:本发明提供了一种促进神经再生和修复神经损伤的药物应用,以Nr4a3作为分子干预靶点,干扰Nr4a3,促进DRG神经元轴突生长。本发明的Nr4a3有可能通过调节DRG神经元轴突生长参与周围神经损伤修复,为神经损伤后的治疗提供新的靶点。
本发明的实施例中,qRT-PCR和western blot发现DRG 神经元体外培养模型(模拟体内坐骨神经损伤)中,随着时间点Nr4a3表达显著下降。同时,通过体外DRG转染Nr4a3siRNA,验证了干扰Nr4a3可以显著促进原代培养的DRG神经元轴突的生长,为周围神经损伤修复提供新的靶点。
附图说明
图1为本发明的实施例1中大鼠DRG 神经元体外培养中Nr4a3的qRT-PCR及Westernblot结果图;其中,图1A为DRG 神经元体外培养,qRT-PCR检测不同时间点Nr4a3的表达情况图;图1B为 Western blot结果显示图。
图2为本发明的实施例2中体外干扰Nr4a3可以显著促进DRG神经元轴突的生长图。其中,图2 A为qRT-PCR检测siRNA处理后,DRG神经元细胞中Nr4a3的mRNA表达水平图。图2B为 DRG神经元细胞Nr4a3 siRNA处理72 h后,细胞免疫组化染色图。其中,左侧:红光为Tuj1, Bar=50 μm;右:Nr4a3 siRNA后,测量所有神经元轴突长度分布图。图2C为体外DRG神经元转染 Nr4a3 siRNA后,所有神经元最长轴突的平均值统计图。
具体实施方式
为使本发明要解决的技术问题、技术方案和优点更加清楚,下面将结合具体实施例进行详细描述。
实施例1 考察大鼠DRG 神经元体外培养中Nr4a3的表达变化
一、原代DRG神经元细胞的提取
DRG 神经元来自成年雄性大鼠,将背根神经节取出后放到解剖液 HA 中,适量 3.3mg/ml 胶原酶消化,37 ℃,90 min。弃胶原酶,加适量 0.25%的胰酶消化,37 ℃,约 20min。用含有10%胎牛血清的 PBS 终止胰酶作用,离心后弃上清。为了去除杂的胶质细胞,用15%的牛血清白蛋白悬浮细胞后离心,弃掉上清。用神经元培养基重悬细胞,过200目筛网后种到用多聚赖氨酸包被的板孔里。
二、DRG细胞RNA提取及qRT-PCR
收取体外培养不同时间点的DRG神经元细胞,提取RNA。 按TRIZOL® Reagent(Invitrogen)说明书提取RNA。使用 TaqMan 反转录试剂盒进行逆转录。逆转录后,采用SYBR® PrimeScript RT-PCR Kit(Takara)进行qRT-PCR,操作按试剂盒说明书进行(以GAPDH作为内参), PCR仪反应程序: Stage 1:95℃ 2 min, Stage 2 (Cycle:40):95℃ 15s,60℃ 1 min;Stage 3:95℃ 15 s,60℃ 1 min,95℃ 15 s。Nr4a3引物序列forward: 5’-CGAGCTCGAAGCCTGAGCAGAGAGCTACTT -3’, reverse: 5’-CCGCTCGAGCGGAGACTAAAGCAAAAATGAT -3’。qRT-PCR结果如图1A所示,结果显示与0 h相比,体外培养的DRG神经元细胞中的Nr4a3表达不断下调。
三、Western blot
收取体外培养不同时间点的DRG神经元细胞,PBS 润洗一遍,加入适量的细胞裂解液(含1%的蛋白酶抑制剂),冰上裂解 5-10 min,至细胞完全裂解;4 ℃离心,13000 rpm,10min,收集上清。BCA法蛋白定量。进行SDS-PAGE电泳,转膜后用5%的脱脂牛奶,室温封闭2 h。孵育一抗,用一抗稀释液稀释 Rabbit anti-Nr4a3 Polyclonal antibody(1:400),室温孵育,过夜。1×TBS 洗3遍,每遍 10 min。用 5%的脱脂牛奶稀释二抗羊抗兔 HRP(1:1000),室温孵育,120 min。1×TBST 洗 3 遍,每遍 10min,1×TBS 洗 1 遍,10 min。在膜上孵育ECL 显色液,室温,1-3 min。显影,观察结果。待胶片晾干后用扫膜仪将结果传输到电脑。Western blot结果如图1B所示,结果显示与0 h相比,体外培养的DRG神经元细胞中的Nr4a3表达不断下调。
实施例2 体外干扰Nr4a3促进DRG神经元轴突生长
一、DRG神经元细胞siRNA转染
Nr4a3的 siRNA 来源于广州锐博生物公司,siRNA-1序列:GCGTACAGATAGTCTGAAA,siRNA-2序列:GCCTTTGATCAAGATGGAA,.使用浓度100 nM。使用转染试剂 Lipofectamine™RNAiMAX 在原代培养的DRG神经元细胞中转染Nr4a3 siRNA及阴性对照 (Control),12 h后更换为正常神经元培养基,48 h后提取细胞总RNA,按实施例1中进行qRT-PCR,检测siRNA处理后,DRG神经元细胞中Nr4a3的mRNA表达水平。如图2A所示,qRT-PCR结果表明,Nr4a3siRNA1和siRNA2均能显著降低DRG神经元细胞中Nr4a3的mRNA表达水平。
二、细胞免疫荧光染色及轴突生长长度测量
DRG神经元细胞Nr4a3 siRNA处理72 h后将细胞培养基弃掉后,用 PBS 润洗一遍,加入4%的多聚甲醛,固定30 min。弃掉多聚甲醛后,PBS 洗三遍,每遍5 min。加入免疫组化封闭液,室温封闭1 h。 用免疫组化一抗稀释液稀释一抗anti-Tuj1 antibody(1:200,Sigma),加好一抗后,4 ℃过夜。 弃掉一抗,PBS洗3遍,每遍5 min。用免疫组化二抗稀释液稀释荧光二抗Cy3 sheep anti-rabbit IgG (1:400,Sigma),加好二抗后,避光室温2 h。弃掉二抗,PBS洗3遍,每遍5 min。 用PBS稀释Hoechest,加好Hoechest后,室温10 min。 弃掉Hoechest,PBS洗3遍,每遍5 min。加入适量荧光封片液,ZEISS正置荧光显微镜下观察,拍照。观察突起的生长情况,拍照并统计各组最长突起长度和各组突起长度的分布。结果显示,Nr4a3 siRNA1和siRNA2体外干扰DRG神经元细胞中的Nr4a3,可以显著促进DRG神经元轴突的生长,且对所有神经元轴突长度的分布进行统计,表明干扰Nr4a3 后,轴突生长的长度偏向长的区间分布,如图2B所示。进一步对体外DRG神经元转染 Nr4a3 siRNA后所有神经元最长轴突的平均值进行计算,发现Nr4a3干扰后,显著增加神经元最长轴突的平均值,如图2C所示,表明干扰DRG神经元细胞中的Nr4a3,可以显著促进DRG神经元轴突的生长。
以上所述是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明所述原理的前提下,还可以作出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 南通大学
<120> Nr4a3在促进神经再生和修复神经损伤方面的应用
<141> 2020-06-18
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 19
<212> DNA
<213> Nr4a3的小干扰RNA 1 序列(Nr4a3 siRNA-1)
<400> 1
gcgtacagat agtctgaaa 19
<210> 2
<211> 19
<212> DNA
<213> Nr4a3的小干扰RNA 2 序列(Nr4a3siRNA-2)
<400> 2
gcctttgatc aagatggaa 19
Claims (8)
1.Nr4a3在制备促进神经再生和修复神经损伤药物中的应用。
2.根据权利要求1所述的Nr4a3在制备促进神经再生和修复神经损伤药物中的应用,其特征在于,所述神经损伤为周围神经系统坐骨神经损伤。
3.根据权利要求1所述的Nr4a3在制备促进神经再生和修复神经损伤药物中的应用,其特征在于,所述药物以Nr4a3作为分子干预靶点,干扰Nr4a3,促进DRG神经元轴突生长。
4.一种促进神经再生和修复神经损伤药物,其特征在于,所述药物至少包括Nr4a3的小干扰RNA。
5.根据权利要求4所述的一种促进神经再生和修复神经损伤药物,其特征在于,所述Nr4a3的小干扰RNA包括Nr4a3 siRNA-1或Nr4a3 siRNA-2,所述Nr4a3 siRNA-1序列为GCGTACAGATAGTCTGAAA,所述Nr4a3siRNA-2序列为GCCTTTGATCAAGATGGAA。
6.Nr4a3在促进神经再生和修复神经损伤方面的应用,其特征在于,包括以下过程:S1、大鼠DRG 神经元体外培养并检测其中Nr4a3的表达情况;S2、体外干扰Nr4a3,能够促进DRG神经元轴突生长。
7.根据权利要求6的Nr4a3在促进神经再生和修复神经损伤方面的应用,其特征在于,所述步骤S1具体包括以下过程:
S1-1、原代DRG神经元细胞的提取
S1-1-1、DRG 神经元来自成年雄性大鼠,将背根神经节取出后放到解剖液 HA 中,加3.3 mg/ml 胶原酶消化,37 ℃,90 min;
S1-1-2、弃胶原酶,加 0.25%的胰酶消化,37 ℃,20 min;
S1-1-3、用含有10%胎牛血清的 PBS 终止胰酶作用,离心后弃上清;
S1-1-4、用 15%的牛血清白蛋白悬浮细胞后离心,弃掉上清;
S1-1-5、用神经元培养基重悬细胞,过200目筛网后种到用多聚赖氨酸包被的板孔里;
S1-2、DRG细胞RNA提取及qRT-PCR
S1-2-1、收取体外培养不同时间点的DRG神经元细胞,提取RNA;
S1-2-2、使用 TaqMan 反转录试剂盒进行逆转录;
S1-2-3、逆转录后,进行qRT-PCR,以GAPDH作为内参, PCR仪反应程序: Stage 1:95℃2 min, Stage 2:95℃ 15 s,60℃ 1 min;Stage 3:95℃ 15 s,60℃ 1 min,95℃ 15 s;Nr4a3引物序列forward: 5’-CGAGCTCGAAGCCTGAGCAGAGAGCTACTT -3’, reverse: 5’-CCGCTCGAGCGGAGACTAAAGCAAAAATGAT -3’;
S1-3、Western blot
S1-3-1、收取体外培养不同时间点的DRG神经元细胞,PBS 润洗一遍,加入的细胞裂解液,冰上裂解 5-10 min,至细胞完全裂解;
S1-3-2、4 ℃离心,13000 rpm,10 min,收集上清;BCA法蛋白定量;
S1-3-3、进行SDS-PAGE电泳,转膜后用5%的脱脂牛奶,室温封闭2 h;
S1-3-4、孵育一抗,用一抗稀释液稀释 Rabbit anti-Nr4a3 Polyclonal antibody(1:400),室温孵育,过夜;1×TBS 洗3遍,每遍 10 min;
S1-3-5、用 5%的脱脂牛奶稀释二抗羊抗兔 HRP(1:1000),室温孵育,120 min;1×TBST洗 3 遍,每遍 10min,1×TBS 洗 1 遍,10 min;
S1-3-6、在膜上孵育 ECL 显色液,室温,1-3 min;显影,观察结果;待胶片晾干后用扫膜仪将结果传输到电脑。
8.根据权利要求6的Nr4a3在促进神经再生和修复神经损伤方面的应用,其特征在于,所述步骤S2具体包括以下过程:
S2-1、DRG神经元细胞siRNA转染
Nr4a3 siRNA-1序列:GCGTACAGATAGTCTGAAA,Nr4a3 siRNA-2序列:GCCTTTGATCAAGATGGAA,使用浓度100 nM;
使用转染试剂 Lipofectamine™ RNAiMAX 在原代培养的DRG神经元细胞中转染Nr4a3siRNA及阴性对照,12 h 后更换为正常神经元培养基,48 h后提取细胞总RNA,进行qRT-PCR,检测siRNA处理后,DRG神经元细胞中Nr4a3的mRNA表达水平;
S2-2、细胞免疫荧光染色及轴突生长长度测量
S2-2-1、DRG神经元细胞Nr4a3 siRNA处理72 h后将细胞培养基弃掉后,用 PBS 润洗一遍,加入4%的多聚甲醛,固定30 min;
S2-2-2、弃掉多聚甲醛后,PBS 洗三遍,每遍5 min;
S2-2-3、加入免疫组化封闭液,室温封闭1 h;
S2-2-4、用免疫组化一抗稀释液稀释一抗anti-Tuj1 antibody(1:200,Sigma),加好一抗后,4 ℃过夜; 弃掉一抗,PBS洗3遍,每遍5 min;
S2-2-5、用免疫组化二抗稀释液稀释荧光二抗Cy3 sheep anti-rabbit IgG (1:400,Sigma),加好二抗后,避光室温2 h;弃掉二抗,PBS洗3遍,每遍5 min;
S2-2-6、用PBS稀释Hoechest,加好Hoechest后,室温10 min; 弃掉Hoechest,PBS洗3遍,每遍5 min;
S2-2-7、加入适量荧光封片液,ZEISS正置荧光显微镜下观察,拍照;观察突起的生长情况,拍照并统计各组最长突起长度和各组突起长度的分布。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010558904.1A CN111643681A (zh) | 2020-06-18 | 2020-06-18 | Nr4a3在促进神经再生和修复神经损伤方面的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010558904.1A CN111643681A (zh) | 2020-06-18 | 2020-06-18 | Nr4a3在促进神经再生和修复神经损伤方面的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111643681A true CN111643681A (zh) | 2020-09-11 |
Family
ID=72342166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010558904.1A Withdrawn CN111643681A (zh) | 2020-06-18 | 2020-06-18 | Nr4a3在促进神经再生和修复神经损伤方面的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111643681A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112301033A (zh) * | 2020-11-24 | 2021-02-02 | 南通大学 | miR-30a-5p及其在促进神经再生和修复周围神经损伤方面的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012100662A (ja) * | 2011-12-05 | 2012-05-31 | Sapporo Medical Univ | 細胞増殖方法ならびに組織の修復および再生のための医薬 |
US20180193386A1 (en) * | 2015-07-03 | 2018-07-12 | Beihao Stem Cell and Regenerative Medicine Research Institutes Co., Ltd. | Compositions and Methods For Reprograming Non-Neuronal Cells Into Neuron-Like Cells |
-
2020
- 2020-06-18 CN CN202010558904.1A patent/CN111643681A/zh not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012100662A (ja) * | 2011-12-05 | 2012-05-31 | Sapporo Medical Univ | 細胞増殖方法ならびに組織の修復および再生のための医薬 |
US20180193386A1 (en) * | 2015-07-03 | 2018-07-12 | Beihao Stem Cell and Regenerative Medicine Research Institutes Co., Ltd. | Compositions and Methods For Reprograming Non-Neuronal Cells Into Neuron-Like Cells |
Non-Patent Citations (5)
Title |
---|
APARNA BANERJEE DIXIT ET AL.: "Genome-wide DNA Methylation and RNAseq Analyses Identify Aberrant Signalling Pathways in Focal Cortical Dysplasia (FCD) Type II", 《SCIENTIFIC REPORTS》 * |
LILI ZHAO ET AL.: "miR-20a Promotes the Axon Regeneration of DRG Neurons by Targeting Nr4a3", 《NEUROSCI. BULL.》 * |
NAGANARI OHKURA ET AL.: "Antisense oligonucleotide to NOR-l, a novel orphan nuclear receptor,induces migration and neurite extension of cultured forebrain cells", 《MOLECULAR BRAIN RESEARCH》 * |
TAKAYUKI HIRANO ET AL.: "Forced expression of NR4A3 induced the differentiation of human neuroblastoma-derived NB1 cells", 《MED ONCOL.》 * |
路智超: "NR4A3在造血发生和分化过程中的功能研究", 《中国优秀硕士学位论文全文数据库基础科学辑》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112301033A (zh) * | 2020-11-24 | 2021-02-02 | 南通大学 | miR-30a-5p及其在促进神经再生和修复周围神经损伤方面的应用 |
CN112301033B (zh) * | 2020-11-24 | 2021-11-19 | 南通大学 | miR-30a-5p及其在促进神经再生和修复周围神经损伤方面的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Watanabe et al. | Self-organized cerebral organoids with human-specific features predict effective drugs to combat Zika virus infection | |
Pastrana et al. | Genes associated with adult axon regeneration promoted by olfactory ensheathing cells: a new role for matrix metalloproteinase 2 | |
Mariani et al. | FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders | |
Simão et al. | Recapitulation of human neural microenvironment signatures in iPSC-derived NPC 3D differentiation | |
JP2020072753A (ja) | ヒト機能性角膜内皮細胞およびその応用 | |
WO2019100727A1 (zh) | Dna四面体在抑制阿尔兹海默细胞凋亡中的应用 | |
CN112553142B (zh) | 一种鼻黏膜上皮细胞3d类器官及其培养方法和应用 | |
EP3600362A1 (en) | Assembly of functionally integrated human forebrain spheroids and methods of use thereof | |
CN112301033B (zh) | miR-30a-5p及其在促进神经再生和修复周围神经损伤方面的应用 | |
Xu et al. | Human midbrain dopaminergic neuronal differentiation markers predict cell therapy outcomes in a Parkinson’s disease model | |
Wong et al. | Machine learning workflows identify a microRNA signature of insulin transcription in human tissues | |
CN111643681A (zh) | Nr4a3在促进神经再生和修复神经损伤方面的应用 | |
WO2007047581A2 (en) | Pulmonary stem cells, related methods and kits | |
Gallagher et al. | Comparative transcriptomic analysis of cultivated limbal epithelium and donor corneal tissue reveals altered wound healing gene expression | |
CN104313131B (zh) | 一种检测小鼠内耳毛细胞的标记分子及应用 | |
RU2768720C2 (ru) | Идентификация и выделение предшественников слуховых клеток человека | |
Mahboudi et al. | Mir-106b cluster regulates primordial germ cells differentiation from human mesenchymal stem cells | |
CN104293926B (zh) | 一种检测小鼠内耳祖细胞的标记分子及应用 | |
CN111269940A (zh) | 一种使用转录因子foxo1直接转分化间充质干细胞为精子的方法 | |
CN104877960B (zh) | miR‑2400显著促进牛骨骼肌卫星细胞增殖的生物功能 | |
CN104278029B (zh) | 一种检测小鼠内耳干细胞的标记分子及应用 | |
CN107345897A (zh) | 一种视网膜感光细胞特异性表面蛋白的筛选方法 | |
Pajanoja et al. | Maintenance of pluripotency in the entire ectoderm enables neural crest formation | |
CN114015686B (zh) | 新的与衰老相关的circRNA、筛选方法及应用 | |
CN114085833A (zh) | 一种miR-25-3p、应用及其应用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200911 |